Most Read Articles
Jairia Dela Cruz, 3 days ago
The potassium-competitive acid blocker vonoprazan demonstrates superior efficacy in the treatment of patients with erosive oesophagitis compared with the proton pump inhibitor lansoprazole, with the results of a small trial showing that the former more rapidly provides complete sustained heartburn relief during the first week of therapy.
01 Mar 2016
Bathing with 2% chlorhexidine gluconate-medicated washcloth is cost-effective for the prevention of central line-associated bloodstream infection (CLABSI), based on a systematic review and meta-analysis of four studies.
31 May 2016
Tacrolimus is safe and effective in inducing and maintaining remission in paediatric patients with biologic refractory inflammatory bowel disease (IBD), according to a study presented at the 49th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition in Athens, Greece.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Infliximab, adalimumab show efficacy in psoriasis and IBD

09 Feb 2018

Infliximab and adalimumab are both effective for the treatment of psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease, while other biologics have shown efficacy for some, but not all, of these indications, according to the results of a systematic review.

To evaluate therapeutic options for patients with psoriasis and concurrent inflammatory bowel disease (IBD), a total of 2,282 articles were identified, of which 132 were selected. These clinical studies, published from 1 January 1947 to 14 February 2017, focused on biologic and systemic psoriasis medications in psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease.

The investigators selected randomized, controlled, double-blinded studies if available and, if not, the next highest level of available evidence.

Both infliximab and adalimumab had shown efficacy in psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease. Ustekinumab was effective against psoriasis, psoriatic arthritis and Crohn’s disease, while certolizumab had demonstrated efficacy in psoriatic arthritis and Crohn’s disease.

On the other hand, etanercept, secukinumab, brodalumab and ixekizumab were effective in psoriasis and psoriatic arthritis, but these medications could induce or worsen IBD. In addition, guselkumab was effective in psoriasis only.

This systematic review was limited by the absence of clinical trials involving treatment specifically for concurrent psoriasis and IBD.

“There is a significant association between psoriasis and IBD. Many treatments for psoriasis and psoriatic arthritis are also used for IBD,” according to the investigators.

In another systematic review, researchers found that biologic therapy was effective and safe for the treatment of hyperkeratotic palmoplantar psoriasis (PP). [Dermatol Ther (Heidelb) 2017;7:425-446]

“Adalimumab, guselkumab, ixekizumab, secukinumab and ustekinumab all showed >80-percent efficacy for the treatment of hyperkeratotic PP, while infliximab and ustekinumab showed moderate efficacy for the treatment of pustular PP, and infliximab was the most efficacious treatment for palmoplantar pustulosis,” they said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 3 days ago
The potassium-competitive acid blocker vonoprazan demonstrates superior efficacy in the treatment of patients with erosive oesophagitis compared with the proton pump inhibitor lansoprazole, with the results of a small trial showing that the former more rapidly provides complete sustained heartburn relief during the first week of therapy.
01 Mar 2016
Bathing with 2% chlorhexidine gluconate-medicated washcloth is cost-effective for the prevention of central line-associated bloodstream infection (CLABSI), based on a systematic review and meta-analysis of four studies.
31 May 2016
Tacrolimus is safe and effective in inducing and maintaining remission in paediatric patients with biologic refractory inflammatory bowel disease (IBD), according to a study presented at the 49th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition in Athens, Greece.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.